Bahl & Gaynor’s DexCom DXCM Stock Holding History

Bahl & Gaynor’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,671	Closed	-$215K	–	338
2023 Q2	$215K	Buy	+1,671	New	+$202K	﹤0.01%	331
2023 Q1	–	Sell	-1,853	Closed	-$210K	–	341
2022 Q4	$210K	Buy	+1,853	New	+$203K	﹤0.01%	328

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bahl & Gaynor's DXCM Position: Q3 2023 in Review

Bahl & Gaynor sold out of DexCom (DXCM) in Q3 2023, closing a stake of 1,671 shares — an estimated $215K sold.

Bahl & Gaynor first reported a position in DXCM in Q4 2022 and held it in 2 quarters. The position peaked at $215K in Q2 2023. 903 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

Bahl & Gaynor reported no remaining DexCom position as of Q3 2023 after selling out during the quarter.
Bahl & Gaynor sold 1,671 DexCom shares in Q3 2023, an estimated $215K.
Bahl & Gaynor first reported a position in DexCom in Q4 2022 and held it in 2 quarters.
Bahl & Gaynor's DexCom position peaked at $215K in Q2 2023.
903 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Bahl & Gaynor's 13F filing for Q3 2023, filed 3 Nov 2023.